Immucor expects buyout to cut into 2009 profit

Blood-testing equipment maker Immucor Inc. expects its $117 million buyout of molecular diagnostics systems maker BioArray Solutions Ltd. to cut into its fiscal 2009 profit.

On Wednesday, the company said it expects profit between $1.11 and $1.15 per share in fiscal 2009, which ends May 31. Revenue will range from $292 million to $300 million, the company said. The projections exclude between 20 cents and 23 cents per share for BioArray buyout, which the company announced in March.

Analysts polled by Thomson Financial expect profit of 98 cents per share, on revenue of $300.6 million. Analyst estimates typically exclude one-time charges.

Immucor said revenue will come from a mix of its new pricing strategy and sales of its Galileo and Echo systems in North America, Japan and Europe.

Shares of Immucor fell 90 cents, or 3.3 percent, to $26 in after-hours electronic trading, after rising 87 cents, or 3.3 percent, to close at $26.90 in the regular session.